Irwin Naturals Inc. (CSE:IWIN) and Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) have signed a Letter of Intent (LOI) entering into a partnership to launch Clinical Research Services across Irwin’s growing US-based network of clinics, Emergence.
Under the LOI, Irwin will invest up to $2 million over the next 12 months to launch initial research services beginning with at least five clinics in Florida.
The two companies said that the partnership would create a leading mental health-focused clinical research platform designed to streamline and accelerate the process of in-human clinical development of new therapies, including seamless patient recruitment, through to US Food and Drug Administration (FDA) application.
READ: Braxia Scientific sees Q2 revenue increase, with in-clinic treatment up 34.5%
They noted that the partnership would support multiple large and small pharmaceutical sponsors, innovative biotechnology companies, medical device companies, and government and non-governmental institutions who seek to carry out the development of new therapies in the area of mental health in the US.
Braxia Scientific CEO Dr Roger McIntyre said that the company was conducting a number of ongoing clinical trials and was currently receiving requests from various pharmaceutical sponsors to support international programs to develop novel therapies in mental health.
“We have been developing a plan to reach a broader market in the US and globally,” he said. “This exciting partnership allows us to expand our expertise in an effective manner by leveraging the existing Irwin infrastructure deployed over a number of states in the US.”
READ: Irwin Naturals inks licensing deal to distribute its THC products in Oregon
Irwin CEO Klee Irwin added: “We are extremely pleased to have reached a new milestone in the development of our clinics by establishing a strategic relationship with Dr McIntyre and his research team.”
“Having an outstanding reputation for scientific expertise, quality clinical research in depression and other mental health disorders areas, that will enable us to further develop our US clinical footprint."
Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
Irwin Naturals’ mission is to heal the world with plant medicine. The company is leveraging its brand as a best-in-class herbal supplement formulator to enter the cannabis and psychedelic industries.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie